HOOKIPA Pharma Announces Initiation of Phase 1b Clinical Trial for HB-500, a Therapeutic HIV Vaccine

In the global battle against the Human Immunodeficiency Virus (HIV), the HB-500 therapeutic vaccine, co-developed by HOOKIPA Pharma Inc. and Gilead Sciences, Inc., has entered the Phase 1b clinical trial stage. This historic progress not only brings new hope to HIV patients but also demonstrates the innovation and determination of the biotechnology field in seeking a cure for this long-term challenge.

Since HIV was discovered in the early 1980s, more than 38 million people worldwide have been infected with the virus. HIV infects and destroys human immune cells, leading to acquired immunodeficiency syndrome (AIDS), posing a severe threat to patients' lives. Although existing antiretroviral therapy (ART) can significantly prolong patients' lives and reduce viral transmission, these treatments can only suppress viral replication and have not been able to completely eradicate HIV from the body, thus requiring patients to undergo lifelong treatment.

On July 1, 2024, withFirst Subject Successfully Receives HB-500 Vaccine Dosing, we have witnessed a pivotal moment in the history of HIV resistance. This progress marks a solid step towards finding a cure for HIV, bringing a new ray of hope to HIV patients worldwide.

The primary objective of the Phase 1b clinical trial is to comprehensively evaluate the safety, tolerability, reactogenicity, and immunogenicity of the HB-500 vaccine. Through in-depth research on these key indicators, the researchers hope to verify the safety of the HB-500 vaccine in humans and explore its potential to stimulate an immune response, providing a scientific basis for further clinical development and ultimately achieving a cure for HIV.

Participants in the Phase 1b clinical trial of the HB-500 vaccine are all HIV-infected individuals who are receiving suppressive combination antiretroviral therapy (cART). The reason for selecting this specific population is that the HIV virus in their bodies has been effectively controlled, providing ideal conditions for evaluating the vaccine's immunogenicity and potential therapeutic effects.

HB-500 Vaccine Utilizes HOOKIPA Pharma's Arenavirus Platform, an Innovative Immunotherapy Technology Designed to Activate and Enhance T-Cell Responses Against Severe Diseases. The Platform is Based on Two Genetically Engineered Replicating Vectors, Which Are Carefully Designed to Replicate Within Host Cells, Thereby Enhancing Antigen Expression and the Persistence of Immune Responses.

Another notable feature of the HB-500 vaccine is its precise targeting of the immunogenic regions of the HIV-1 virus. By conducting an in-depth analysis of the genetic sequence of the HIV-1 virus, researchers selected highly conserved regions as antigens, which exhibit a high degree of consistency across different variants of the HIV-1 virus, thereby enhancing the broad applicability and efficacy of the vaccine.

HOOKIPA Pharma CEO Joern Aldag stated, "We have achieved impressive findings in the preclinical studies of HB-500, and we are thrilled to have initiated the Phase 1b trial. Our team, along with the exceptional partnership from Gilead, has worked tirelessly to reach this significant milestone."

Although the Phase 1b clinical trial of the HB-500 vaccine has been initiated, it is important to recognize that all clinical trials come with inherent risks. These risks include, but are not limited to, adverse reactions that participants may experience, the vaccine potentially failing to achieve the desired immune response, and the trial data possibly being insufficient to support conclusions regarding the vaccine's safety and efficacy.

With the launch of the Phase 1b clinical trial for the HB-500 vaccine, HOOKIPA Pharma Inc. has taken a solid step forward in the pursuit of a cure for HIV. This trial not only has potential direct implications for participating patients but also holds profound significance for future treatment options for millions of HIV-infected individuals worldwide. If the HB-500 vaccine can demonstrate its safety and efficacy, it could become a key factor in transforming the landscape of HIV treatment.

Source of the Article：https//globenewswire.com/news-release/2024/07/01/2907081/0/en/HOOKIPA-Pharma-Announces-First-Person-Dosed-in-Phase-1b-Clinical-Trial-of-HB-500-for-the-Treatment-of-HIV.html